SecBot SecBot
8-K ·Filed Aug 10, 2026

ABCL

AbCellera Biologics Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001703057-26-000053
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The strong Phase 2 data significantly de-risks ABCL635 and supports best-in-class positioning. Traders should monitor for Phase 3 initiation, additional data at medical conferences later this year, and regulatory interactions. The stock may re-rate upward given the large unmet need and potential to capture share from approved NK3R small molecules.

DirectionBullish
Confidencehigh
Horizonweeks

ABCL635

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.34
T+0 close · Aug 10, 2026 · via day close
Latest settled
+30.41%
T+60 · $12.18
Vs SPY
+32.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $9.34entry
  2. T+1 · 3mo ago +4.50%α +4.82% · $9.76
  3. T+5 · 3mo ago +19.91%α +19.96% · $11.20
  4. T+20 · 2mo ago +22.48%α +23.40% · $11.44
  5. T+60 · 14d ago +30.41%α +32.82% · $12.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbCellera announced positive top-line Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes). The single 600 mg subcutaneous dose met primary endpoints with statistically significant reductions in VMS frequency (83% vs 33% placebo, p<0.001) and severity (58% vs 12% placebo, p<0.001) at week 4, with a favorable safety profile (no SAEs or severe AEs in the treatment group). The data suggest best-in-class potential versus approved small-molecule NK3R antagonists and support advancement to late-stage development.

Key Facts

  • Phase 2 trial enrolled 92 postmenopausal women; randomized 1:1 to single 600 mg SC ABCL635 or placebo.
  • Mean placebo-adjusted reduction in VMS frequency at week 4: 5.3 events/day (p<0.001); 83% reduction ABCL635 vs 33% placebo.
  • Mean placebo-adjusted reduction in VMS severity score at week 4: 1.1 points (p<0.001); 58% reduction ABCL635 vs 12% placebo.
  • No serious adverse events or Grade 3+ AEs in the ABCL635 group; headache (28.2%) and fatigue (13.0%) most common AEs.
  • 84% of ABCL635 patients rated symptoms as 'Much Better' or 'Moderately Better' on PGI-C vs 27% placebo.
  • Significant improvement in sleep disturbance (PROMIS-SD-SF-8b T-score change -5.5 vs placebo, p<0.001).
  • Company plans regulatory interactions for late-stage development in VMS due to menopause and oncology treatments.

Financial Impact

Phase 2 success de-risks ABCL635, targeting a $6B+ total addressable market for non-hormonal VMS treatments per management estimates. No financial data in filing.

pipeline valuefuture revenue potential

Risk Factors

  • Phase 3 failure or safety issues in larger, longer-duration trials
  • Competitive pressure from approved NK3R antagonists (fezolinetant, elinzanetant) and other non-hormonal therapies
  • Regulatory delays or additional clinical data requirements
  • Cross-trial comparisons are not head-to-head and may not replicate in Phase 3

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001703057-26-000053
Document: abcl635phase2clinicalupd.htm0001703057-26-000053
Document: a2026-08x10abcl635phase2.htm0001703057-26-000053
Document: 0001703057-26-000053-index-headers.html0001703057-26-000053
Document: 0001703057-26-000053-index.html0001703057-26-000053
Document: 0001703057-26-000053.txt0001703057-26-000053

Track record

16 reports on ABCL

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Viewing Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026